SCHEMBL2688399

SCHEMBL2688399

Cc1nc2cc(-c3nc4ccccc4o3)ccc2n1N1CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.45
▸ ALDH1A1 P00352 7/20 0.45
▸ NPC1 O15118 6/20 0.45
▸ HPGD P15428 6/20 0.45
▸ RAB9A P51151 5/20 0.45
▸ SMN1; SMN2 Q16637 5/20 0.45
▸ HCRTR1 O43613 2/20 0.45
▸ NFKB1 P19838 2/20 0.45
▸ STAT1 P42224 2/20 0.45
▸ NFKB2 Q00653 2/20 0.45
▸ RELA Q04206 2/20 0.45
▸ HSD17B10 Q99714 4/20 0.44
▸ MAPT P10636 3/20 0.44
▸ USP2 O75604 3/20 0.44
▸ TSHR P16473 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ CASP3 P42574 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ SENP8 Q96LD8 1/20 0.44
▸ SENP7 Q9BQF6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2687887 0.79 LMNA (0.56) LMNAGAA
SCHEMBL2688684 0.79 MET (0.44) KDM4EALDH1A1NPC1HPGDRAB9A
SCHEMBL2688110 0.78 NPC1 (0.55) KDM4EALDH1A1NPC1HPGDRAB9A
SCHEMBL10219836 0.78 BRD4 (0.51) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL2686294 0.77 BRD4 (0.46) KDM4EALDH1A1NPC1HPGDRAB9A
Dimethylamine SCHEMBL2687204 0.77 MET (0.42) KDM4EALDH1A1NPC1HPGDRAB9A
SCHEMBL2688265 0.76 ALDH1A1 (0.47) KDM4EALDH1A1NPC1HPGDRAB9A
SCHEMBL2687383 0.75 KDM4E (0.55) KDM4EALDH1A1NPC1HPGDRAB9A
SCHEMBL2686759 0.75 NPC1 (0.49) KDM4EALDH1A1NPC1HPGDRAB9A
SCHEMBL2686770 0.75 MAPK1 (0.55) KDM4EALDH1A1NPC1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
EP-2436683-B1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL CO (JP) 2014-05-14 — — EP disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS BDNF, NGF, NTRK2 KDM4E 4538/4885ALDH1A1 1772/4885NPC1 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback